DK3368658T3 - Ekspansion af ikke-hæmatopoetiske vævsresidente gamma-delta-T-celler og anvendelser af disse celler - Google Patents

Ekspansion af ikke-hæmatopoetiske vævsresidente gamma-delta-T-celler og anvendelser af disse celler Download PDF

Info

Publication number
DK3368658T3
DK3368658T3 DK16788539.1T DK16788539T DK3368658T3 DK 3368658 T3 DK3368658 T3 DK 3368658T3 DK 16788539 T DK16788539 T DK 16788539T DK 3368658 T3 DK3368658 T3 DK 3368658T3
Authority
DK
Denmark
Prior art keywords
cells
delta
expansion
applications
hematopoietic tissue
Prior art date
Application number
DK16788539.1T
Other languages
Danish (da)
English (en)
Inventor
Adrian Hayday
Oliver Nussbaumer
Richard Woolf
Original Assignee
Cancer Research Tech Ltd
King S College London
The Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1519198.4A external-priority patent/GB201519198D0/en
Priority claimed from GBGB1612731.8A external-priority patent/GB201612731D0/en
Application filed by Cancer Research Tech Ltd, King S College London, The Francis Crick Institute Ltd filed Critical Cancer Research Tech Ltd
Application granted granted Critical
Publication of DK3368658T3 publication Critical patent/DK3368658T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2315Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
DK16788539.1T 2015-10-30 2016-10-31 Ekspansion af ikke-hæmatopoetiske vævsresidente gamma-delta-T-celler og anvendelser af disse celler DK3368658T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1519198.4A GB201519198D0 (en) 2015-10-30 2015-10-30 Expansion of gamma delta t cells resident in non-haematopoietic tissue and uses of these cells
GBGB1612731.8A GB201612731D0 (en) 2016-07-22 2016-07-22 Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
PCT/EP2016/076264 WO2017072367A1 (en) 2015-10-30 2016-10-31 EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS

Publications (1)

Publication Number Publication Date
DK3368658T3 true DK3368658T3 (da) 2022-08-01

Family

ID=57211532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16788539.1T DK3368658T3 (da) 2015-10-30 2016-10-31 Ekspansion af ikke-hæmatopoetiske vævsresidente gamma-delta-T-celler og anvendelser af disse celler

Country Status (16)

Country Link
US (2) US11618885B2 (enExample)
EP (2) EP3368658B1 (enExample)
JP (3) JP2018533373A (enExample)
KR (2) KR20250093576A (enExample)
CN (1) CN108473958A (enExample)
AU (2) AU2016344779B2 (enExample)
CA (1) CA3003077A1 (enExample)
DK (1) DK3368658T3 (enExample)
ES (1) ES2925261T3 (enExample)
IL (3) IL295838B2 (enExample)
MX (2) MX2018005207A (enExample)
MY (1) MY198084A (enExample)
PH (1) PH12018500926A1 (enExample)
PL (1) PL3368658T3 (enExample)
PT (1) PT3368658T (enExample)
WO (1) WO2017072367A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
EP3681996B1 (en) 2017-09-15 2024-08-07 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2020027193A1 (ja) * 2018-07-31 2020-02-06 国立大学法人三重大学 γδ型T細胞への遺伝子導入方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CN113423820A (zh) * 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
PH12021551475A1 (en) 2019-01-07 2022-05-02 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
CN112029719B (zh) * 2019-06-04 2024-05-03 北京医明佳和生物科技有限公司 纯化的双阴性t细胞及其制备和应用
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ T細胞集団
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
CA3228168A1 (en) 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
WO2023053994A1 (ja) * 2021-09-29 2023-04-06 アイ ピース, インコーポレイテッド 幹細胞の製造方法
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
JPWO2023176896A1 (enExample) * 2022-03-18 2023-09-21
EP4504247A1 (en) 2022-04-04 2025-02-12 Gammadelta Therapeutics Ltd Novel gene armoring
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
CN121532496A (zh) 2023-07-20 2026-02-13 武田药品工业株式会社 用于制备γδT细胞的无网格方法
CN118165933B (zh) * 2024-05-14 2024-07-16 成都美杰赛尔生物科技有限公司 组合物、提高cd39-cd69-t细胞比例的方法
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
CN118853566B (zh) * 2024-09-26 2025-05-09 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤浸润淋巴细胞的培养方法及培养基

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421573T1 (de) 1998-11-04 2009-02-15 Therapure Biopharma Inc Verfahren zur herstellung von gamma delta t zellen
US20060246520A1 (en) * 2003-05-23 2006-11-02 Institut National De La Sante Et De La Recherche Medicale Gamma delta t cell-mediated therapy
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
PT2710123T (pt) * 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
CN104293734B (zh) * 2014-09-28 2018-01-09 上海云舜生物技术有限公司 一种人γδT细胞的制备方法
CN104711224A (zh) * 2015-01-09 2015-06-17 天津大学 一种提高人Vδ2T细胞扩增效率的体外培养方法及应用
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2016198906A1 (fr) * 2015-06-10 2016-12-15 Arcelormittal Acier a haute résistance et procédé de fabrication

Also Published As

Publication number Publication date
ES2925261T3 (es) 2022-10-14
US20180312808A1 (en) 2018-11-01
JP2018533373A (ja) 2018-11-15
PH12018500926A1 (en) 2018-11-05
IL295838A (en) 2022-10-01
US20230099491A1 (en) 2023-03-30
EP4148124A1 (en) 2023-03-15
MX2018005207A (es) 2018-09-19
AU2016344779A1 (en) 2018-06-14
HK1253954A1 (en) 2019-07-05
CN108473958A (zh) 2018-08-31
US11618885B2 (en) 2023-04-04
MX2022011003A (es) 2022-10-07
WO2017072367A1 (en) 2017-05-04
IL315329A (en) 2024-10-01
IL295838B2 (en) 2025-02-01
IL258985B2 (en) 2023-02-01
KR20180098235A (ko) 2018-09-03
RU2018119684A3 (enExample) 2020-03-17
KR102821381B1 (ko) 2025-06-13
JP2024069306A (ja) 2024-05-21
JP7451468B2 (ja) 2024-03-18
EP3368658B1 (en) 2022-07-06
KR20250093576A (ko) 2025-06-24
EP3368658A1 (en) 2018-09-05
PL3368658T3 (pl) 2022-11-28
CA3003077A1 (en) 2017-05-04
AU2022283768A1 (en) 2023-02-02
MY198084A (en) 2023-07-31
RU2018119684A (ru) 2019-12-02
IL258985B (en) 2022-10-01
IL295838B1 (en) 2024-10-01
BR112018008293A2 (en) 2018-10-30
PT3368658T (pt) 2022-08-17
JP2022002517A (ja) 2022-01-11
AU2016344779B2 (en) 2023-01-05
IL258985A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
DK3368658T3 (da) Ekspansion af ikke-hæmatopoetiske vævsresidente gamma-delta-T-celler og anvendelser af disse celler
DK4218738T3 (da) Partikeldråbestrukturer og fremgangsmåder til fremstilling og anvendelse af disse
IL280718A (en) T cell receptor constructs and uses thereof
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
DK3459201T3 (da) Design af fælles ressourcekort over DM-RS og PT-RS
DK3667980T3 (da) Indikation og modtagelse af ressourceposition
DK3349351T3 (da) Integreret apparat og system til udnyttelse af solenergi
PL3350220T3 (pl) Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania
DK3553180T3 (da) Fremgangsmåde til konstruktion af enkeltcellesekventeringsbibliotek og anvendelse deraf
DK3185854T3 (da) Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse
DK3701973T3 (da) Plasmabaseret film og fremgangsmåder til fremstilling og anvendelse af samme
EP3586367A4 (en) STABLE PEROVSKITE SOLAR CELL
EP3362032A4 (en) SYSTEMS AND METHOD FOR THE PRODUCTION AND USE OF GEL MICROBALLETS
DK3577213T3 (da) Mikrobielle celler, fremgangsmåder til frembringelse af disse og anvendelser deraf
DK3606760T3 (da) Indretning og fremgangsmåde til belægning af overflader
IL283818A (en) Bedside automated cell engineering system and methods
DK3388519T3 (da) Vesikulær adapter og anvendelser deraf i konstruktion af nukleinsyrebibliotek og sekvensering
EP3908294A4 (en) Modified cell expansion and uses thereof
DK3443608T3 (da) Elektrokemisk celler med udformede strømningsfelter og fremgangsmåder til fremstilling deraf
DK3045925T3 (da) Fremgangsmåde og system til iterativ bestemmelse af ladetilstanden for en battericelle
DK3188051T3 (da) Systemer og fremgangsmåder til generering af søgeskabeloner
DK3642331T3 (da) Fremgangsmåde til udvidelse af T-celler og anvendelser deraf
DK3319948T3 (da) Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse
DK3404258T3 (da) Systemer og fremgangsmåder til stabilisering af effektgenerering
DK3322695T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse